Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-047680
Filing Date
2025-03-31
Accepted
2025-03-31 16:01:03
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 18965
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 17945
3 EX-99.2 ck0001669811-ex99_2.pdf EX-99.2 72729
  Complete submission text file 0000950170-25-047680.txt   146123
Mailing Address 171 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-475-2820
Surrozen, Inc./DE (Subject) CIK: 0001824893 (see all company filings)

EIN.: 301374889 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91867 | Film No.: 25792992
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ACCESS INDUSTRIES, INC. 40 WEST 57TH STREET, 28TH FLOOR NEW YORK NY 10019
Business Address C/O ACCESS INDUSTRIES, INC. 40 WEST 57TH STREET, 28TH FLOOR NEW YORK NY 10019 212-247-6400
AI Biotechnology LLC (Filed by) CIK: 0001942670 (see all company filings)

EIN.: 842172770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G